How this company measures up on the fundamentals that matter
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $44, 78% above fair value of $25. Passes all ethical screens. Ranks better than 53% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | HERR AMY E. | Director | 6,636 | $315,874 | |
| 2026-05-08 | HERR AMY E. | Director | 6,636 | $320,386 | |
| 2026-05-05 | HIPPEL JAMES | Chief Financial Officer | 62,000 | $2,951,200 | |
| 2026-05-05 | KELDERMAN KIM | Chief Executive Officer | 26,692 | $1,270,539 | |
| 2026-05-05 | BOHNEN SHANE | General Counsel | 8,400 | $399,840 | |
| 2026-05-01 | CROUSE STEVEN C. | Officer | 794 | — | |
| 2026-04-22 | HIPPEL JAMES | Chief Financial Officer | 62,000 | — | |
| 2026-04-22 | KELDERMAN KIM | Chief Executive Officer | 11,344 | — | |
| 2026-04-14 | KELDERMAN KIM | Chief Executive Officer | 36,500 | $1,737,400 | |
| 2026-04-02 | BOHNEN SHANE | General Counsel | 2,259 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 7 Feb2025 | Tim Walberg | Republican | buy | 15K–50K |
| 21 May2026 | Josh Gottheimer | Democrat | buy | 1K–15K |
| 2026-04-13 | Josh Gottheimer | Democrat | Purchase | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15